Address:

15 Beech Lane , Macclesfield , Cheshire SK10 2DR

Telephone:

01625 505 100

Fax:

01625 505 199

Email:

info@cyprotex.com

Website:

www.cyprotex.com

Drug discovery technology and information company

Chairman:

Steve Harris (.5% holding)

Chief Executive:

Anthony Baxter (.5% holding)

CFO:

John Dootson (0% holding)

Chief Commercial Off:

Simon Bury (0% holding)

Bank of Scotland: 15.2%

Intercapital Private Group: 15.1%

R. J. Koch: 9.8%

D. Leahy: 5.8%

Rensburg Sheppards Investment Management: 5.8%

Nominated Adviser:

Singer Capital Markets

Nominated Broker:

Singer Capital Markets

Solicitors:

n/a

Auditors:

Ernst & Young

Registrar:

Capita Registrars

Entry on AIM:

15/2/2002

Issue Price:

29.0p

Interim Results:

Aug

Final Results:

Mar

Year End:

Dec

Accounts Due:

Jun

Int div payment:

n/a

Fin div payment:

n/a

Int net div per share:

nil

Fin net div per share:

nil

	2009	2008
Turnover:	£5.00m	£5.18m
Pre-tax profit:	£ 0.46m	£ 0.54m
EPS:	0.26 p	0.36 p

Cyprotex in £2.7m US takeover 06/08/2010

Cyprotex 22/03/2010

Cyprotex broadens its scope 17/03/2010

Demand disappoints Cyprotex 20/11/2009

Small-Cap Stock Picks 14/08/2009